查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138415

先兆子痫诊断的全球市场-2022-2029

Global Preeclampsia Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

先兆子痫的发病率在全球范围内呈上升趋势。对其诊断和治疗的需求激增预计将推动先兆子痫诊断市场的增长。

预计对其诊断和治疗的需求激增将推动市场增长。

对其诊断和治疗的需求激增预计将推动先兆子痫诊断市场的增长。根据先兆子痫基金会的数据，全世界每年有超过 1000 万女性患上先兆子痫，先兆子痫每年导致约 250 万例早产。这种疾病影响发达国家和发展中国家的新生儿和母亲。根据世界卫生组织（WHO）的数据，发展中国家先兆子痫的患病率是发达国家的七倍。此外，BioMed Central (BMC) 报告称，新兴经济体中先兆子痫的发病率在 1.8% 至 16.7% 之间。非洲大陆约有 10% 的孕妇患有这种疾病。孕产妇和围产期死亡率和发病率的上升预计将增加对孕妇先兆子痫早期诊断的需求。

此外，增加对用于检测指示先兆子痫的生物标誌物的创新测试的研发预计将在预测期内促进市场增长。例如，2022 年 11 月，都柏林圆形医院 RCSI 妇产科的一个研究小组在 2022 年世界糖尿病日之前启动了三项研究，调查女性患糖尿病的经历和影响。这三项研究由地区卫生研究委员会 (HRB) 和欧盟委员会资助，总额为 110 万欧元。爱尔兰试验将检验阿司匹林在改善糖尿病孕妇健康方面的作用。这是第一项研究低剂量阿司匹林对预防糖尿病女性先兆子痫（妊娠期高血压）影响的试验。

2020 年 7 月，赫尔辛基大学的研究人员发现，HLA-G 基因调节出生时的性别比例。这项研究强化了先前的发现，即男性胎儿易患先兆子痫。

预计新兴国家缺乏对先兆子痫的认识将阻碍市场增长。

由于医疗保健专业人员对这种情况的有效筛查工具缺乏认识，以及准妈妈对与先兆子痫相关的体征和症状的了解越来越多，这可能会促进先兆子痫的发展诊断市场在预测期内迅速发展。

行业分析

全球先兆子痫诊断市场根据各种行业因素（包括波特五力、监管和报销分析、价值链分析、定价分析、技术进步、流行病学等）对市场进行深入分析。

全球先兆子痫诊断市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按测试类型划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 先兆子痫患病率上升
    • 先兆子痫诊断的技术进步
  • 限制
    • 新兴国家缺乏对先兆子痫的认识
  • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 流行病学
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 技术进步
  • 未满足的需求

第 6 章按产品类型分析

  • 设备
  • 消耗品

第 7 章按测试类型

  • 验血
  • 尿液分析

第 8 章最终用户

  • 医院
  • 诊断中心
  • 专科诊所
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • Diabetomics, Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer Inc.
  • Siemens Healthineers AG
  • DRG INSTRUMENTS GMBH
  • Metabolomic Diagnostics Ltd.
  • Bayer AG
  • Sera Prognostics（*List is not exhaustive）

第12章 DataM

简介目录
Product Code: DMMD2588

Market Overview

Preeclampsia Diagnostics Market size was valued US$ 1.03 billion in 2021 and is estimated to reach US$ 1.24 billion by 2029, growing at a CAGR of 11.0% during the forecast period (2022-2029).

Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. It is characterized by elevated blood pressure and excessive protein in the urine of pregnant women which can cause the baby delivered preterm and smaller than usual. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. If it is not diagnosed at an early stage, then it may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death. For instance, according to the Preeclampsia Foundation, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 infant deaths each year globally.

Market Dynamics

The rising incidences of preeclampsia globally. The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market.

Rapidly growing demand for its diagnosis and treatments are expected to drive market growth.

The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market. According to the Preeclampsia Foundation, more than 10 million women globally develop preeclampsia every year, and around 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in developed and developing nations. According to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in emerging countries as compared to developed countries. Also, as per a report by BioMed Central (BMC), the incidence of preeclampsia ranges from 1.8% to 16.7% in developing economies. It affects around 10% of pregnant women in the African continent. The rise in maternal & perinatal mortality and morbidity rates is projected to increase the demand for early diagnosis of preeclampsia among pregnant women.

In addition, increasing research and development to innovative new tests to detect biomarkers indicating preeclampsia is expected to boost the market growth over the forecast period. For instance, in November 2022, a team of researchers at the RCSI Department of Obstetrics and Gynaecology at the Rotunda Hospital, Dublin launched three research studies that examined the experiences and impact of diabetes in women, ahead of World Diabetes Day 2022. The three studies have been awarded total funding of €1.1 million in this region by the Health Research Board (HRB) and the European Commission. The IRELAnD Trial will examine the role that aspirin improves the health of pregnant women with diabetes. This is the first study to examine the impact of low-dose aspirin for the prevention of preeclampsia (high blood pressure during pregnancy) in women with diabetes.

Also in July 2020, researchers from the University of Helsinki have shown that HLA-G gene regulates the male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia.

Lack of awareness about Preeclampsia in developing countries is expected to hamper the market growth.

The lack of awareness about the effective screening tools for the condition among the healthcare providers and increasing knowledge about the signs & symptoms associated with preeclampsia among pregnant mothers and are likely to boost the preeclampsia diagnostics market growth rapidly over the forecast period.

Industry Analysis

The global preeclampsia diagnostics Market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory & Reimbursement Analysis, Value Chain Analysis, Pricing Analysis, Technological Advancements, Epidemiology etc.

Segment Analysis

Blood tests segment is expected to hold the largest market share in global preeclampsia diagnostics market

The blood tests accounted for the largest market share of the preeclampsia diagnostics market in 2022, owing to the several advantages of blood tests in detecting the biomarkers efficiently which are responsible for preeclampsia. Several organizations are highly adopting blood tests as a better test for the detection of preeclampsia. With advancements in technology, new tests are being introduced in the market, which are further boosting the blood test market growth. For instance, the NHS England approved two blood test products named Elecsys sFlt-1 and PlGF immunoassays of F. Hoffmann-La Roche under the 'Innovation and Technology Payment' program in June 2022. The NHS aims to implement the usage of innovative products within the hospitals in Europe and enhance the accessibility of diagnostic tools for preeclampsia among healthcare professionals to detect pregnancy-induced hypertension.

Geographical Analysis

North America region holds the largest market share in the global preeclampsia diagnostics market

North America region is dominating the global preeclampsia diagnostics market accounting for the largest market share in 2022, owing to the increasing healthcare expenditure, adoption of highly advanced products, growing awareness towards preeclampsia among the patients and healthcare providers regarding the severity of the condition. The increasing prevalence of preeclampsia is leading to an increase in medical treatment cost among women with preeclampsia and their newborns. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG), the total cost of maternal healthcare with preeclampsia was around one-third of the total U.S. healthcare costs of women with preeclampsia.

Competitive Landscape

The Preeclampsia Diagnostics market is dominated by major players including Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, among others.

Global Preeclampsia Diagnostics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Overview: Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.

Product Portfolio: Elecsys sFlt-1/PlGF- immunoassays for preeclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical conext.

The global preeclampsia diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Preeclampsia
    • 4.2.2. Technological Advancements in Preeclampsia Diagnostic
  • 4.3. Restraints:
    • 4.3.1. Lack of awareness about Preeclampsia in developing countries
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Technological Advancements
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment.
  • 6.3. Market Attractiveness Index, By Product Type Segment
    • 6.3.1. Instruments*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Consumables

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment.
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Blood Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Urine Analysis

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment.
    • 8.1.2. Market Attractiveness Index, By End-User Segment
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Centers
  • 8.4. Specialty Clinics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Diabetomics, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. F. Hoffmann-La Roche Ltd
  • 11.4. PerkinElmer Inc.
  • 11.5. Siemens Healthineers AG
  • 11.6. DRG INSTRUMENTS GMBH
  • 11.7. Metabolomic Diagnostics Ltd.
  • 11.8. Bayer AG
  • 11.9. Sera Prognostics (*List is not exhaustive)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us